HomeCompareTSRYF vs ABBV

TSRYF vs ABBV: Dividend Comparison 2026

TSRYF yields 6.07% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.0K in total portfolio value
10 years
TSRYF
TSRYF
● Live price
6.07%
Share price
$2.15
Annual div
$0.13
5Y div CAGR
2.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$1,227.34
Full TSRYF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TSRYF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSRYFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSRYF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSRYF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSRYF
Annual income on $10K today (after 15% tax)
$516.33/yr
After 10yr DRIP, annual income (after tax)
$1,043.24/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $20,823.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSRYF + ABBV for your $10,000?

TSRYF: 50%ABBV: 50%
100% ABBV50/50100% TSRYF
Portfolio after 10yr
$68.2K
Annual income
$13,476.53/yr
Blended yield
19.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TSRYF
No analyst data
Altman Z
2.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSRYF buys
0
ABBV buys
0
No recent congressional trades found for TSRYF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSRYFABBV
Forward yield6.07%3.12%
Annual dividend / share$0.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.7%40.6%
Portfolio after 10y$31.7K$104.7K
Annual income after 10y$1,227.34$25,725.73
Total dividends collected$9.1K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TSRYF vs ABBV ($10,000, DRIP)

YearTSRYF PortfolioTSRYF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,324$623.84$11,559$438.51$235.00ABBV
2$12,795$678.04$13,494$640.86$699.00ABBV
3$14,425$735.32$15,951$945.97$1.5KABBV
4$16,231$795.73$19,152$1,413.89$2.9KABBV
5$18,227$859.34$23,443$2,146.38$5.2KABBV
6$20,429$926.22$29,391$3,321.96$9.0KABBV
7$22,855$996.40$37,948$5,265.87$15.1KABBV
8$25,525$1,069.95$50,795$8,596.74$25.3KABBV
9$28,458$1,146.91$71,034$14,549.41$42.6KABBV
10$31,678$1,227.34$104,715$25,725.73$73.0KABBV

TSRYF vs ABBV: Complete Analysis 2026

TSRYFStock

Treasury Wine Estates Limited operates as a wine company primarily in Australia, New Zealand, Asia, Europe, the Middle East, Africa, and the Americas. The company engages in the viticulture and winemaking; and marketing, sale, and distribution of wine. Its wine portfolio includes luxury, premium and commercial wine brands, such as 19 Crimes, Acacia Vineyard, Annie's Lane, Beaulieu Vineyard, Belcreme de Lys, Beringer Vineyards, Blossom Hill, Cavaliere d'Oro, Coldstream Hills, Devil's Lair, EMBRAZEN, Etude, Fifth Leg, Heemskerk, Hewitt Vineyard, Ingoldby, Jamieson's Run, Killawarra, Leo Buring, Lindeman's, Maison de Grand Esprit, Matua, Penfolds, Pepperjack, Rawson's Retreat, Rosemount Estate, Run Riot, Saltram, Samuel Wynn & Co, Secret Stone, Seppelt, Shingle Peak, Sledgehammer, Squealing pig, St Huberts, Stags' Leap Winery, Stellina di Notte, Sterling Vineyards, T'Gallant, The Walking Dead Wine, Wolf Blass, Wynns Coonawarra Estate, and Yellowglen. The company also provides contract bottling services to third parties; and sells grape and bulk wine. It owns and leases 8,362 planted hectares of vineyards in Australia and New Zealand; 2,702 planted hectares in California, including the Napa Valley, Sonoma County, Lake County, and Central Coast; 90 planted hectares in France's Bordeaux region; and 154 planted hectares in Tuscany, Italy. The company markets and sells its products to distributors, wholesalers, retails chains, independent retailers, and on-premise outlets, as well as directly to consumers. Treasury Wine Estates Limited was founded in 1843 and is headquartered in Melbourne, Australia.

Full TSRYF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TSRYF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSRYF vs SCHDTSRYF vs JEPITSRYF vs OTSRYF vs KOTSRYF vs MAINTSRYF vs JNJTSRYF vs MRKTSRYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.